Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Lack of association between single-nucleotide polymorphisms of pro- and anti-inflammatory cytokines and HTLV-1-associated myelopathy / tropical spastic paraparesis development in patients from Rio de Janeiro, Brazil

  • 1, 2,
  • 3,
  • 1Email authorView ORCID ID profile,
  • 4,
  • 3,
  • 1,
  • 2 and
  • 2
BMC Infectious Diseases201818:593

https://doi.org/10.1186/s12879-018-3510-1

  • Received: 27 April 2018
  • Accepted: 8 November 2018
  • Published:
Open Peer Review reports

Abstract

Background

HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a progressive neurological and inflammatory disease, associated with HTLV-1 infection. HAM/TSP neurological disease is a consequence of an inflammatory reaction, and adaptive immune responses, through the secretion of anti-inflammatory and pro-inflammatory cytokines, play an important role in the outcome of infection and disease progression. Studies addressing the association between cytokines functional single nucleotide polymorphisms and HAM/TSP development are scarce.

Methods

The genetic polymorphisms of cytokine genes were evaluated in HAM/TSP patients (n = 68) and in asymptomatic HTLV-1 positive carriers (n = 83) from Rio de Janeiro, Brazil, in a case-control study. HTLV-1 infected patients were genotyped for SNPs in five cytokine genes: TNFA-308G/A, IL6-174G/C, IFNG + 874 T/A, TGFB at the codons + 10 T/C and + 25G/C, IL10-592C/A and -819C/T, and -1082A/G and proviral load (PVL) was quantified. Associations between genotypes, haplotypes, clinical outcome and pro viral load were evaluated.

Results

Lack of association between the cytokine polymorphisms and disease outcome was observed. The genotypes TNFA-308GG, IL6-174GG/GC, IL10-592AA and -819CC and TGFb1 high producers phenotypes were correlated with higher PVL in HAM/TSP patients versus asymptomatic carriers.

Conclusions

We did not observe association between cytokine polymorphisms and risk for HAM/TSP development in Brazilian HTLV-1 infected individuals, regardless of differences in PVL between HAM/TSP versus asymptomatic carriers in specific cytokine polymorphisms.

Keywords

  • Cytokine
  • HAM/TSP
  • HTLV-1
  • SNP
  • Proviral load

Background

The HTLV-1 virus is the etiological agent of two major diseases: adult T cell leukemia and the neurological disease HTLV-associated myelopathy / tropical spastic paraparesis (HAM/TSP), a progressive neurological and inflammatory disease of the central nervous system. Although many of the infected individuals are asymptomatic, approximately 2–5% of the infected individuals will develop HAM/TSP [1]. This neurological disease could be the consequence of an inflammatory network that results in damage of the spinal cord [2], but this association is still poorly understood.

Tax viral protein plays an important role in the regulation of the virus genome acting in proviral genome transcription by interacting with several cellular signaling pathways that modulate the expression of cytokine and chemokine genes [3]. The IFN-γ secreted by HTLV-1 infected CD4+T cells and the virus recognition by CD8+T lymphocytes in the central nervous system induces production of other cytokines, such as the myelinotoxic TNF-α. This event, together with the hemodynamic changes and interactions mediated by adhesion molecules among circulating lymphocytes and endothelial cells, which contribute to the location of spinal cord injury, is known as a “bystander” damage hypothesis. The involvement of cytokines in the outcome of HAM/TSP is associated with the “bystander” damage hypothesis [1]. Among the potential immunopathological findings, high levels of IFN-γ, TNF-α and IL-6 have been detected in patients with HAM/TSP, which seem to contribute for the breakthrough of the blood–brain barrier and resulting in immunopathology and neurological symptoms [4]. In addition, HAM/TSP patients showed dysregulation in TGF-β signaling, affecting Treg function and contributing for disease pathology [5]. Differences in IL-2, IL-4, IL-10, IL-12p70, TNF-α and IFN-γ levels were also found in the supernatants of cultured peripheral blood mononuclear cells (PBMC) from HAM/TSP and AC [6]. Recent publication showed no difference in plasma cytokine levels among AC and HAM/TSP patients. However, cerebrospinal fluid levels of cytokines (ITAC, IFN-γ, IL-5, IL-8 and TNF-α) were higher in HAM/TSP compared with AC patients, indicating that those cytokines might be used as disease markers of neurologic manifestation in long-term HTLV-1 infected individuals [7].

Single nucleotide polymorphisms (SNPs) might have influence in the cytokine production. It has been shown that IFNG + 874 T/A [8], TNF -308G/A [9, 10], IL6 -174G/C [11], IL10–1082A/G, -819C/T and -592C/A [12], and TGFB at the codons + 10 T/C and + 25G/C [13, 14] SNPs alter the expression of the related cytokines in pathological or physiological conditions. Many of these polymorphisms have been associated with inflammatory and infectious diseases [1519]. Indeed, IFNG + 874A/T [20], IL6 -174G/C [21], and IL10 -592C/A and -819C/T [22] have been associated with HAM/TSP development or HTLV-1 infection.

Because these specific polymorphisms are associated with changes in cytokines production and many inflammatory and infectious diseases, and those cytokines have important role in HTLV-1 infection, it would be important evaluate the association between these polymorphisms and HAM/TSP development. Studies addressing the role of SNPs that might alter cytokine production and HTLV-1 infection are scarce. Therefore, our aim was to determine in a case-control study if SNPs of pro- and anti-inflammatory cytokines in HAM/TSP and AC patients were related to disease outcome.

Methods

Study population

HAM/TSP patients and ACs were randomly recruited from a cohort of approximately 700 individuals attended at the Laboratory for Clinical Research in Neuroinfection, INI-FIOCRUZ, Rio de Janeiro, RJ, Brazil. The diagnosis of HAM/TSP patients was performed according to the World Health Organization diagnostic criteria [23]. The patients were mainly from Rio de Janeiro, Brazil, and the follow-up mean was 128.85 ± 54.44 months. The Institutional Ethics Committee approved the study, and all subjects provided written informed consent. Demographic data included information regarding a self-identified skin color as described as white or non-white (black and mixed persons), sex and age.

DNA extraction

Five milliliters of whole blood were collected in EDTA-containing tubes, and DNA extraction was carried out by a commercial kit from Puregene (Gentra Systems Inc., Minneapolis, MN, USA), following the manufacturer’s instructions.

Genotyping

SNPs in five cytokine genes, TNFA-308G/A, TGFB at codons + 10 T/C and TGFB + 25G/C, IL10-1082A/G, -592C/A and -819C/T, IL6-174G/C, IFNG + 874 T/A were genotyped through sequence-specific primers-polymerase chain reaction technique (SSP-PCR) using a commercial kit by Cytokine Genotyping Tray (One Lambda, Inc., Canoga Park, CA, USA). This technique has allowed us genotyped eight SNPs of five cytokine genes, simultaneously, through PCR reaction. The SSP-PCR technique provides an accurate, simple, and economical means of detecting polymorphisms of these important pro- and anti-inflammatory cytokine genes.

Ninety-six well microtiter® trays with dried primers in each reaction well were filled with 10 μl of a mix containing dNTPs (8 μl, provided by the manufacturer), Taq polymerase (1 μl at 5 U/μl) and DNA sample (1 μl, 100 ng) per reaction well. The reaction was performed in a Veriti thermocycler (Applied Biosystems, Foster City, CA, USA) with the follow instructions: one cycle of 130 s at 96 °C, 60s at 63 °C; nine cycles of 10s at 96 °C, 60s at 63 °C; twenty cycles of 10s at 96 °C, 50s at 59 °C and 20s at 72 °C; and ending at 4 °C.

After completing the PCR reaction, the samples were transferred to 2.5% agarose gel stained with ethidium bromide (0.5 μg/ml), and were electrophoresed at 140–150 V. After electrophoretic run, the gel was transferred for an ultraviolet transilluminator and photographed for analysis. The presence or absence of gel band from each amplified reaction well determined the SNP identification.

Phenotype analysis for IL10-1082A/G, -819C/T and -592C/A SNPs were demonstrated as low (ACC/ACC, ACC/ATA, ATA/ATA), intermediate (GCC/ACC, GCC/ATA) and high (GCC/GCC) IL-10 producers, as described by the commercial kit.

Proviral load quantification

HTLV-1 PVL DNA from peripheral blood leucocytes was measured by real-time PCR assay (SmartCycle II; Cepheid) using the TaqMan system (Applied Biosystems, Foster City, California, USA), through the amplification of a 159-bp fragment of the tax gene. As a reference, a standard curve was generated using the human β-globin gene and DNA from the TARL-2 cell line, which contains a single copy of the provirus HTLV-1, to establish the tax gene quantification. PVL was calculated in peripheral blood leukocytes (PBL) from each volunteer following the equation: [(copy number of tax gene) / (copy number of β-globin gene/2)] × 100 [24].

Statistical analysis

Proviral load statistical analysis between genotypes/phenotypes and disease groups was performed by an ordinary two-way ANOVA with Bonferroni post-test for multiple comparisons correction [25], considering results with p-values < 0.05 statistically significant. Nonparametric data were evaluated by Kruskal-Wallis and Mann-Whitney tests and a Spearman correlation, and association between qualitative variables (alleles, genotypes and phenotypes frequencies) was tested by chi-square, Cochran-Armitage or Fisher’s exact test. P-values from tables with any significant result were corrected using Bonferroni correction for multiple comparisons. Results with a p-value < 0.05 were considered statistically significant. All analyses were performed using the software GraphPad Prism 6.0 or R version 3.1.0 [26].

Results

Characteristics of HTLV-1 infected patients and proviral load

Sixty-eight HAM/TSP patients and 83 ACs were enrolled. The demographic data are shown in Table 1. We did not observe differences related to ethnic background, gender and age between the grouped volunteers. Proviral load was higher in the HAM/TSP patients than AC group(p < 0.04, Table 1).
Table 1

Demographic variables distribution according with clinical condition of HAM/TSP patients

Variables

HAM/TSP

Asymptomatic

OR (CI:95%)

p-value

Corrected p-valued

Skin color (n/%)

 White

40 (46.5)

46 (53.5)

1

  

 Non-White

28 (43.1)

37 (56.9)

0.87 (0.45–1.66)

0.67a

1.00

Sex (n/%)

 Male

27 (41.5)

38 (58.5)

1

  

 Female

41 (47.7)

45 (52.3)

1.28 (0.67–2.47)

0.45a

1.00

Age

 Mean (SD)

57.8 (11.3)

53.3 (14.7)

1.03 (1–1.05)

0.04b

0.16

PVL

Median (IQR)

7.1(4.0–9.8)

1.3 (0–4.9)

1.14 (1.06–1.24)

< 0.01c

< 0.04

HAM/TSP HTLV-1-associated myelopathy / Tropical spastic paraparesis, OR odds ratio, CI confidence interval, SD standard deviation, PVL proviral loads

aChi-Square or Fisher Exact test. bT-test for comparison of difference means and cKruskal-Wallys test. dAdjusted p-value using Bonferroni correction for multiple comparisons

Distribution of cytokines genotypes in HAM/TSP and AC

All analyzed genotype frequencies were in Hardy-Weinberg equilibrium for both the HAM/TSP and AC groups (data not shown). No significant differences were observed at positions TNFA-308G/A, IL6-174G/C, IFNG + 874 T/A and TGFB at codons + 10 T/C and + 25G/C between the HAM/TSP and AC groups regarding genotypic, allelic and phenotypic analysis in the dominant, recessive or co-dominant genetic models (Tables 2 and 3).
Table 2

Analysis of associations between TNFA-308G/A, IL6-174G/C and IFNG + 874 T/A polymorphisms and risk of HAM/TSP development

Polymorphisms

HAM/TSP

Asymptomatic

  

n (%)

n (%)

OR (IC:95%)

p-value

TNFA-308G/A

 GG

55 (82.1)

69 (83.1)

1

0.98

 GA

12 (17.9)

13 (15.7)

1.16 (0.48–2.75)

 

 AA

0

1 (1.2)

0 (NA)

 

 GG (low)

55 (82.1)

69 (83.1)

1

1

 GA + AA (high)

12 (17.9)

14 (16.9)

1.08 (0.45–2.52)

 

 AA

0

1 (1.2)

1

1

 GA + GG

67 (100)

82 (98.8)

0 (NA)

 

Alleles

  G

122 (91.0)

151 (91.0)

1

1

  A

12 (9.0)

15 (9.0)

0.99 (0.44–2.19)

 

IL6-174G/C

 GG

48 (71.6)

56 (68.3)

1

0.88

 GC

16 (23.9)

24 (29.3)

0.78 (0.37–1.62)

 

 CC

3(4.5)

2 (2.4)

1.75 (0.28–13.7)

 

 CC (low)

3 (4.5)

2 (2.4)

1

0.66

 GC + GG (high)

64 (95.5)

80 (97.6)

0.53 (0.07–3.31)

 

 GG

48 (71.6)

56 (68.3)

1

0.79

 GC + CC

19 (28.4)

26 (31.7)

0.85 (0.42–172)

 

Alleles

  G

112(83.6)

136 (82.9)

1

1

  C

22 (16.4)

28 (17.1)

0.95 (0.51–1.76)

 

IFNG + 874 T/A

 AA (low)

34 (50.7)

34 (43.6)

1

0.86

 AT (intermediate)

26 (38.8)

40 (51.3)

0.65 (0.33–1.29)

 

 TT (high)

7(10.4)

4 (5.1)

1.75 (0.48–7.20)

 

 AA

34 (50.7)

34 (43.6)

1

0.49

 AT+TT

33 (49.3)

44 (56.4)

0.75 (0.39–1.44)

 

 TT

7 (10.4)

4 (5.1)

1

0.35

 AT+AA

60 (89.6)

74 (94.9)

0.46 (0.12–1.61)

 

Alleles

  A

94 (70.1)

108 (69.2)

1

0.97

  T

40 (29.9)

48 (30.8)

0.96 (0.58–1.58)

 

HAM/TSP HTLV-1 associated myelopathy tropical spastic paraparesis, Asymptomatic HTLV-1 patients, OR odds ration with confident interval, Chi-square 2 × 2 or 3 × 2 contingent tables, Fisher exact or Cochran-Armitage tests

Table 3

Analysis of associations between TGFB codon 10 T/C and codon 25G/C polymorphisms and risk of HAM/TSP development

Polymorphisms

HAM/TSP

Asymptomatic

  

n (%)

n (%)

OR (IC:95%)

p-value

TGFB Codon 10

 T/T

25 (37.3)

24 (28.9)

1

 

 T/C

29 (43.3)

45 (54.2)

0.62 (0.3–1.28)

 

 C/C

13 (19.4)

14 (16.9)

0.89 (0.35–2.29)

0.61

 Alleles

  T

79 (59.0)

93 (55.4)

1

 

  C

55 (41.0)

73 (43.5)

0.89 (0.56–1.41)

0.70

TGFB Codon 25

 G/G

56 (83.6)

71 (85.5)

1

 

 G/C

10 (14.9)

11 (13.3)

1.15 (0.45–2.92)

 

 C/C

1 (1.5)

1 (1.2)

1.27 (0.05–32.54)

0.74

 T/C G/G High

47 (70.1)

58 (69.9)

1

 

 T/C G/C; C/C G/G; T/T G/C Intermediate

15 (22.4)

24 (28.9)

0.77 (0.36–1.62)

 

 C/C G/C; C/C C/C; T/T C/C Low

5 (7.5)

1 (1.2)

6.17 (0.95–120.4)

0.51

HAM/TSP HTLV-1 associated myelopathy tropical spastic paraparesis, Asymptomatic HTLV-1 patients, OR odds ration with confident interval, Chi-square 2 × 2 or 3 × 2 contingent tables, Fisher exact or Cochran-Armitage tests

The IL10-1082A/G -592C/A and -819C/T polymorphisms (Table 4) showed the highest frequencies for allele A at position -1082A/G and allele C at -819C/T and -592C/A positions in both groups, with no significant differences in allelic distribution. The polymorphisms IL10 -592C/A and IL10–819C/T were estimated by a single analysis due to the complete linkage disequilibrium between the two SNPs with D’ = 0.99. The A allele of IL10 -592C/A was always linked with the T allele of IL10–819 T/C and C with C. No differences were observed regarding genotypic distribution between the HAM/TSP and AC groups in co-dominant genetic models at all positions. Moreover, at position IL10-1082A/G, despite we found in a dominant model a 2.4-fold risk factor for HAM/TSP outcome (OR = 2.42 [1.2–4.97], p = 0.01) in IL10-1082A/G plus G/G carriers, the data lost significance due correction for multiple comparisons. Analysis including sex, skin color and age did not interfere with the risk for disease progression (p < 0.01, the data not shown). IL10 phenotypic (low, intermediate and high IL-10 producers) and haplotype (Tables 4 and 5) association showed no influence in HAM/TSP outcome.
Table 4

Analysis of associations between IL10-1082A/G, -819C/T and -592C/A polymorphisms and risk of HAM/TSP development

Polymorphisms

HAM/TSP

AC

Crude

  

n (%)

n (%)

OR (IC:95%)

p-value

Corrected p-value

IL10-1082G/A

 A/A (low)

20 (32.3)

38 (53.5)

1

  

 G/A (intermediate)

34 (54.8)

24 (33.8)

2.69 (1.28–5.79)

  

 G/G (high)

8 (12.9)

9 (12.7)

1.69 (0.56–5.1)

0.07

0.21

 A/A

20 (32.3)

38 (53.5)

1

  

 G/A G/G

42 (67.7)

33 (46.5)

2.42 (1.2–4.97)

0.01

0.07

 Alleles

  A

74 (59.7)

100 (70.4)

1

  

  G

50 (40.3)

42 (29.6)

1.61 (0.97–2.70)

0.07

0.21

IL10–819/−592 a

 C/C and C/C

25 (43.3)

29 (40.8)

1

  

 C/T and C/A

31 (50.0)

27 (38.0)

1.33 (0.63–2.8)

  

 T/T and A/A

6 (9.7)

15 (21.2)

0.46 (0.15–1.33)

0.38

1

 C/C and C/C

25 (40.3)

29 (40.8)

1

  

 C/T + T/T and C/A + A/A

37 (59.7)

42 (59.2)

1.02 (0.51–2.05)

1

1

 T/T and A/A

6 (9.7)

15 (21.2)

1

  

 C/C + C/T and C/C + C/A

56 (90.3)

56 (78.8)

2.5 (0.94–7.44)

0.12

0.84

Phenotype

 ACC/ACC, ACC/ATA, ATA/ATA (Low)

20 (32.3)

38 (53.5)

1

  

 GCC/ACC, GCC/ATA (Intermediate)

34 (54.8)

24 (33.8)

2.69 (1.28–5.79)

  

 GCC/GCC (High)

8 (12.9)

9 (12.7)

1.69 (0.56–5.10)

0.07

0.21

HAM/TSP HTLV-1 associated myelopathy tropical spastic paraparesis, Asymptomatic HTLV-1 patients, OR odds ration with confident interval, Chi-square 2 × 2 or 3 × 2 contingent tables, Fisher exact or Cochran-Armitage tests

a-819 and -592 are in linkage disequilibrium

Table 5

Haplotype distribution of the IL-10 (−1082G/A,-819C/T and-592C/A) according with the clinical condition

Haplotypes

HAM/TSP

Asymptomatic

 

N

(%)

N

(%)

OR (IC:95%)

p-valuea

GCC

56

(41.18)

54

(32.53)

1

 

ATA

49

(29.52)

69

(50.74)

0.64 (0.36–1.12)

 

ACC

31

(22.79)

43

(25.9)

0.62 (0.34–1.13)

0.19

HAM/TSP HTLV-1 associated myelopathy tropical spastic paraparesis, Asymptomatic HTLV-1 patients, OR odds ration with confident interval

aChi-square 3 × 2 contingent tables

Association with cytokine genotypes and HTLV-1 proviral load

Besides the PVL was higher in HAM/TSP than in AC, we found an association in TNFA-308GG (low producer), IL6GG/GC genotypes (high producer) and high TGF-β phenotype carriers between the HAM/TSP and the AC groups (Fig. 1). IL10-592CC and IL10–819CC (p = 0.0072) genotypes were associated with high PVL in HAM/TSP patients compared with the AC group, as shown in Fig. 2. No further association was identified between the different genotypes or phenotypes when the HAM/TSP or AC patients were analyzed. These results point to a lack of association between the PVL and these cytokine polymorphisms in our set of HTLV-1-infected Brazilian patients.
Fig. 1
Fig. 1

HTLV-1 pro viral load according with cytokines genotypes and phenotypes in HAM/TSP versus AC. The proviral load was expressed as percentage of infected blood leukocytes. a, b and c represent TNFA-308G/C, IL6-174GC genotypes and d represent TGFB1 phenotypes. Statistical significances are indicated according with p value

Fig. 2
Fig. 2

HTLV-1 pro viral load according with IL10 genotypes and phenotypes in HAM/TSP versus AC. The proviral load was expressed as percentage of infected blood leukocytes. a and b represent IL10–1082G/A and IL-10 -592A/C and -819C/T genotypes. c represents IL-10 phenotype. Statistical significances are indicated according with p value

Discussion

HAM/TSP could be the consequence of an inflammatory response of the host immune system; however, the majority of HTLV-1-infected individuals remain asymptomatic, indicating that HTLV-1 infection by itself is not sufficient to induce HAM/TSP. Neurons and glial cells are damaged by toxic or inflammatory products released from HTLV-1-infected T cells and the bystander damage by activated cytotoxic lymphocytes in the central nervous system [27]. Cytokines production varies among individuals, due in part to genetic factors and, in particular, the presence of polymorphisms in important regulatory regions, such as promoter regions. In this study, we aimed to establish an association between polymorphisms in cytokine-related genes (TNFA, IL6, IFNG, TGFB and IL10) and disease outcome. Our results demonstrated that there was no association between TNFA-308G/A, IL6-174G/C, IFNG + 874 T/A, TGFB at codons + 10 T/C and + 25G/C, and IL10-1082G/A, -819C/T and -592C/A polymorphisms and development of HAM/TSP in our set of the Brazilian population. To the best of our knowledge, few studies addressed information on cytokine SNPs and HTLV-1 infection in the Brazilian population.

In vitro studies have shown that HTLV-1 infected lymphocytes transpose the blood-brain barrier, changing its permeability by secretion of IL-1α and TNF-α, which increases the migration of lymphocytes through this site [28]. This migration could enhance the inflammatory response in the nervous system, causing damage in neural cells in vivo. Polymorphism in the promoter region of the TNFA-308G/A was described by Wilson et al. 1992 [29], where the replacement of the allele guanine TNFA (−308G or TNF1) for adenine in the TNFA allele (−308A or TNF2) has been associated with high production of this cytokine in European populations [29]. The TNFA-308G/A polymorphism was analyzed in adult T-cell leukemia/lymphoma versus AC in Japanese population, and no association between this SNP and disease outcome was found [20]. In our set of individuals typed for TNFA-308G/A polymorphism, we also did not find an association between this SNP and the HAM/TSP or AC groups. However, an association between the genotype TNFA-308GG (low producer) and high PVL was observed. Starling et al. 2013 showed an inverse correlation between TNF-α production and PVL in HAM/TSP patients [30], corroborating our results and indicating a possible protective role of TNF-α in the control of pro viral load. Our data suggest a possible effect of TNFA-308GG genotype in PVL not related to disease outcome.

The IL6 -174G/C is associated with changes in cytokine production, where G allele carriers show higher production of IL-6 compared to C allele carriers [11]. Gadelha and colleagues [21] described no association between HAM/TSP and AC in IL6 -174G/C in a Northeast Brazilian population, although this SNP was a risk factor for HAM/TSP when compared with oligosymptomatic patients. Although none of the IL-6 genetic background was associated with HAM/TSP outcome, we observed an increased level of PVL in HAM/TSP patients carrying the higher IL-6 producer (IL6-174GG and CC) genotypes, indicating that a high level of this inflammatory cytokine could be related to a worse scenario in HAM/TSP patients. In addition, IL-6 and TGF-β may induce the differentiation of a Th17 cell profile and increase central nervous system inflammation [31].

In HAM/TSP patients, there is a predominance of Th1 cytokines such as IFN-γ, reduction in Th2 cytokines such as IL-4 and IL-10, and increased production of neurotoxic cytokines affecting regions along the spinal cord [32]. The IFN-γ serum concentration is higher in HAM/TSP individuals than in asymptomatic individuals [6, 30]. Located in the first intron of the IFNG gene, the SNP + 874 T/A contributes to IFN-γ production, with T allele carriers presenting higher production of IFN-γ compared to A allele carriers [8]. Recently, Queiroz et al. 2018 showed higher prevalence of the IFNG + 874 T/A T allele among AC compared to HTLV-1 symptomatic carriers, although no differences in genotypes distribution were detected [20]. Queiroz et al. data agree with our results regard genotype distribution and PVL, differently of allelic distribution, where we did not find differences. This discordance might be due to different study approaches. Queiroz et al. enrolled in their study, HTLV-1 symptomatic carriers with diverse clinical manifestations, such as rheumatism, condition absent in our study. In addition, the patients of that study belonged to North region of Brazil, where differences in migration history and genetics background might occur compared to our study. Our results, in agreement with a previous study [33], demonstrated no significant differences for allele and genotype frequencies of the IFNG + 874 T/A SNP between HAM and AC. In our set of the Brazilian population, there was no statistical influence on any genotypes of IFNG + 874 T/A and PVL in the HAM/TSP or AC groups. However, our results were in discordance with those published by Rocha-Junior et al. [33], who reported a significant association between PVL and the IFNG + 874AA genotype, where this SNP was associated with low PVL. In addition to the two populations belonging to Brazil, the study also had a group included by Rocha-Junior that was from São Paulo State, where high Asiatic frequency is present; our study groups did not include any Asiatic individuals.

It has been shown that TGF- β signaling is critical for Foxp3 expression and T regulatory cells functions in HAM/TSP patients [34]. HAM/TSP patients showed low levels of TGF-β receptor II (TGF-βRII) and Smad7 (a TGF-β–inducible gene) in CD4+ T cells, when compared to healthy donors. In addition, TGF-βRII expression was inversely correlated with the HTLV-1 PVL. This evidence suggests that HTLV-1 can modulate the immune tolerance affecting both regulatory and effector T cells and contributing to the pathogenesis of HAM/TSP [5]. HTLV-1 infection in patients with Sjogren’s Syndrome led to an enhanced serum level of TGF-β and may be important for increased HTLV PVL [35]. The haplotype TG from the SNPs of TGFB at the codons + 10 T/C and + 25G/C has been associated with high production of this cytokine [13]. We did not observe association with these SNPs and HAM/TSP development. However, in our study, we observed higher PVL in HAM/TSP patients TGF-β high producers (+10TT or TC, and + 25GG) compared to AC, suggesting a role of this cytokine in control of the viral replication and disease prognosis. Additional factors might affect the expression of TGF-β during the HTLV-1 infection, changing the gene expression levels regardless the polymorphisms influence [5, 36, 37]. To the best of our knowledge, there is no previous work describing the TGFB SNP in HAM/TSP patients.

HTLV-1 infection in HAM/TSP patients does not alter the expression of IL-10 when compared with AC patients [38]. SNPs in the IL10 gene are controversially associated with the HAM/TSP outcome. A Japanese population showed an association between the IL10 -592A allele and a protective effect, reducing risk of HAM/TSP [39]; however, this SNP was considered to be a risk factor for developing HTLV-1 infection and disease in an Iranian population [22]. No association between IL10 SNPs and HAM/TSP outcome was observed in a Brazilian population [21] in a high-risk HTLV-1 prevalence area with 9.4/1000 habitants [40]. In our set of Brazilian population enrolled from Rio de Janeiro City, an intermediate HTLV-1 prevalence risk area, with 4.7/1000 habitants [40] there was no association with the disease outcome. At position IL10–1082A/G, an Iranian population showed no association with HAM/TSP in a co-dominant genetic model [22]. There were no previous reports describing the SNP in this position in Brazilian HTLV-1-infected individuals. Our results showed a predominance of intermediate producers of IL10-1082AG and GG genotypes among the HAM/TSP individuals (OR 2.42 [1.2–4.97] p = 0.01), predisposing to disease outcome, although the data lost significance after Bonferroni correction for multiple comparisons. Low-producer haplotypes (IL10-1082A, − 819 T and -592A) have been previously associated with AC or HAM/TSP compared with healthy controls [40]; however, no association was described between AC and HAM/TSP groups, as described in this study. Our results demonstrated that only IL10–819CC and -592AA carriers, presenting high levels of IL10 production, have the highest PVL when the HAM/TSP group was compared with the AC group.

The infection caused by HTLV-1 elicits a robust immune response with many factors affecting the cytokines gene expression, such as genetic population’s background, virus subtypes, immunomodulation and individual health status. Indeed, it has been shown that different subtypes of HTLV-1 are region restricted, besides the genetic background of ethnicities across the world [41]. This fact could explain association between polymorphisms of cytokine genes, such as IL10 -592C/A and IL10–1082A/G, and HTLV-1 infection in some specific populations. On the other hand, some polymorphisms, such as TNF -308G/A, IFNG + 874 T/A, IL6 -174G/C, are repeatedly not associated with the disease, regardless genetic background population, suggesting irrelevant role in the HTLV-1 infection. However, more studies in different populations are needed to confirm this hypothesis. Despite no association with disease development, some of these polymorphisms in cytokine genes, such as IFNG + 874 T/A, TNF -308G/A, IL6 -174G/C, TGFB + 10 T/C and + 25G/C, IL10–819C/T and -592C/A might change PVL, indicating a role of this polymorphisms in the controlling of the viral replication and disease prognosis.

Our study might be analyzed considering its limitations such as the number of patients enrolled and the unavailability to measure cytokines concentrations in plasma or cultured cells in the patients. As we used convenience samples, we had limitations regard sample size and biological material to perform the analysis. Despite these polymorphisms are well established to modulate the cytokines production, is not clear its role on the HTLV-1 infection. Future studies addressing the role of these polymorphisms in different populations, associated with the cytokines production, might clarify the role of these functional SNPs in the HTLV-1 infection.

Conclusion

In conclusion, besides the importance given to pro- and anti-inflammatory cytokines in the outcome of HAM/TSP, we could not affirm that TNFA-308G/A, IL6-174G/C, IFNG + 874 T/A, TGFB at the codons + 10 T/C and + 25G/C, IL10-592C/A and -819C/T, and -1082A/G polymorphisms are related to either disease progression, even those related with the amount of secreted cytokines. Genetic background may be studied in other sets of populations to determine and understand the complex role of cytokine networks in HTLV-1 infection and improve the clinical studies for this disease.

Abbreviations

AC: 

Asymptomatic carriers

HAM/TSP: 

HTLV-1-associated myelopathy/tropical spastic paraparesis

HTLV-1: 

Human T-lymphotropic virus 1

PVL: 

Proviral load

SNP: 

Single nucleotide polymorphism

Declarations

Acknowledgements

We would like to thank Wiley’s English Language Editing Service for the manuscript English Language revision.

Funding

This work was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico [Grant No. 477734/07–3] and Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (INI/Fiocruz). All supporters did not participate or influenced in study design, collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available since the data contains particular medical records and individual privacy could be compromised, but are available from the corresponding author on reasonable request.

Authors’ contributions

DS, LCP and MJAS made substantial contributions to study conception and design. AQ-CA and MJAS contributed to patient’s clinical care and follow-up. DS, LCP and MSBQ contributed to acquisition of data. DS, LCP, EHR, MSBQ, GMF-S, MGB-A, AQ-CA and MJAS made substantial contributions to analysis and interpretation of data. DS, LCP, EHR, MSBQ, MGB-A, AQ-CA and MJAS were involved in drafting the manuscript. DS, LCP, EHR, MGB-A, AQ-CA and MJAS were involved in revising the manuscript critically for important intellectual content. All authors contributed for intellectual content of the manuscript. All authors have read and approved the final version of your manuscript.

Ethics approval and consent to participate

This study was approved by the National Institute of Infectious Disease Ethics Committee and all subjects provided written informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Laboratory of Immunology and Immunogenetics in Infectious Diseases, Evandro Chagas National Institute of Infectious Diseases, FIOCRUZ, Avenida Brasil, 4365, Manguinhos, Rio de Janeiro, RJ, 21040-360, Brazil
(2)
Laboratory for Clinical Research in Neuroinfections, Evandro Chagas National Institute of Infectious Diseases, FIOCRUZ, Rio de Janeiro, RJ, Brazil
(3)
Histocompatibility and Cryopreservation Laboratory, Policlinica Piquet Carneiro, Rio de Janeiro State University (UERJ), Rio de Janeiro, RJ, Brazil
(4)
Clinical Research Platform, Evandro Chagas National Institute of Infectious Diseases, FIOCRUZ, Rio de Janeiro, RJ, Brazil

References

  1. Araujo AQC, Silva MTT. The HTLV-1 neurological complex. Lancet Neurol. 2006;5:1068–76.View ArticleGoogle Scholar
  2. Yamano Y, Sato T. Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis. Front Microbiol. 2012;3:389.View ArticleGoogle Scholar
  3. Banerjee P, Rochford R, Antel J, Canute G, Wrzesinski S, Sieburg M, et al. Proinflammatory cytokine gene induction by human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 tax in primary human glial cells. J Virol. 2007;81:1690–700.View ArticleGoogle Scholar
  4. Goncalves DU, Proietti FA, Barbosa-Stancioli EF, Martins ML, Ribas JG, Martins-Filho OA, et al. HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) inflammatory network. Inflamm Allergy Drug Targets. 2008;7:98–107.View ArticleGoogle Scholar
  5. Grant C, Oh U, Yao K, Yamano Y, Jacobson S. Dysregulation of TGF-beta signaling and regulatory and effector T-cell function in virus-induced neuroinflammatory disease. Blood. 2008;111:5601–9.View ArticleGoogle Scholar
  6. Montanheiro PA, Penalva de Oliveira AC, Smid J, LMI F, Olah I, da S Duarte AJ, et al. The elevated interferon gamma production is an important immunological marker in HAM/TSP pathogenesis. Scand J Immunol. 2009;70:403–7.View ArticleGoogle Scholar
  7. Rosa DV, Magno LA, Pereira NC, Romanelli LC, Albuquerque MR, Martins ML, et al. Plasma and cerebrospinal fluid levels of cytokines as disease markers of neurologic manifestation in long-term HTLV-1 infected individuals. Biomark Med. 2018;12:447–54.View ArticleGoogle Scholar
  8. Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol. 2000;61:863–6.View ArticleGoogle Scholar
  9. Kroeger KM, Carville KS, Abraham LJ. The −308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol. 1997;34:391–9.View ArticleGoogle Scholar
  10. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997;94:3195–9.View ArticleGoogle Scholar
  11. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998;102:1369–76.View ArticleGoogle Scholar
  12. Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P. Polymorphic haplotypes of the interleukin-10 5′ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum. 1999;42:1101–8.View ArticleGoogle Scholar
  13. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation. 1998;66:1014–20.View ArticleGoogle Scholar
  14. Stanczuk GA, Tswana SA, Bergstrom S, Sibanda EN. Polymorphism in codons 10 and 25 of the transforming growth factor-beta 1 (TGF-beta1) gene in patients with invasive squamous cell carcinoma of the uterine cervix. Eur J Immunogenetics Off J Br Soc Histocompat Immunogenetics. 2002;29:417–21.View ArticleGoogle Scholar
  15. Jahan I, Ahammad RU, Farzana KS, Khalid MM, Islam MB, Rahman MI, et al. Tumor necrosis factor-alpha -863C/a polymorphism is associated with Guillain-Barré syndrome in Bangladesh. J Neuroimmunol. 2017;310:46–50.View ArticleGoogle Scholar
  16. Mao Z-R, Zhang S-L, Feng B. Association of IL-10 (−819T/C, −592A/C and -1082A/G) and IL-6 -174G/C gene polymorphism and the risk of pneumonia-induced sepsis. Biomark Biochem Indic Expo Response Susceptibility Chem. 2017;22:106–12.Google Scholar
  17. Mera-Ramírez A, Castillo A, Orobio Y, Gómez MA, Gallego-Marin C. Screening of TNFα, IL-10 and TLR4 single nucleotide polymorphisms in individuals with asymptomatic and chronic cutaneous leishmaniasis in Colombia: a pilot study. BMC Infect Dis. 2017;17:177.View ArticleGoogle Scholar
  18. Liu Q, Li W, Li D, Feng Y, Tao C. The association of interleukin-10 -1082, −819, −592 polymorphisms and tuberculosis risk. Saudi Med J. 2015;36:407–17.View ArticleGoogle Scholar
  19. Nattermann J, Vogel M, Nischalke HD, Danta M, Ahlenstiel G, Michalk M, et al. The transforming growth factor-beta high-producer genotype is associated with response to hepatitis C virus-specific therapy in HIV-positive patients with acute hepatitis C. AIDS Lond Engl. 2008;22:1287–92.View ArticleGoogle Scholar
  20. Queiroz MAF, Azevedo VN, EDSG A, TCF M, Guimarães Ishak MO, Ishak R, et al. IFNG +874A/T Polymorphism Among Asymptomatic HTLV-1-Infected Individuals Is Potentially Related to a Worse Prognosis. Front Microbiol. 2018;9:795.View ArticleGoogle Scholar
  21. Gadelha SR, Junior Alcântara LC, Costa GC, Acosta AX, Rios D, Kashima S, et al. Correlation between polymorphisms at interleukin-6 but not at interleukin-10 promoter and the risk of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis in Brazilian individuals. J Med Virol. 2008;80:2141–6.View ArticleGoogle Scholar
  22. Shirdel A, Azarpazhooh MR, Sahebari M, Ghanbari M, Mirfeizi SZ, Hutchinson I, et al. Association of IL-10 gene polymorphisms and human T Lymphotropic virus type I-associated myelopathy/tropical spastic Paraparesis in north-east of Iran (Mashhad). Iran J Basic Med Sci. 2013;16:258–63.PubMedPubMed CentralGoogle Scholar
  23. Osame M. Rewiew of WHO Kagoshima meeting and diagnostic guidelines for HAM/TSP. In: Human Retrovirology: HTLV. New York: Blattner W; 1990. p. 191–7.Google Scholar
  24. Silva MTT, Harab RC, Leite AC, Schor D, Araújo A, Andrada-Serpa MJ. Human T lymphotropic virus type 1 (HTLV-1) proviral load in asymptomatic carriers, HTLV-1-associated myelopathy/tropical spastic paraparesis, and other neurological abnormalities associated with HTLV-1 infection. Clin Infect Dis Off Publ Infect Dis Soc Am. 2007;44:689–92.View ArticleGoogle Scholar
  25. Dunn OJ. Multiple comparisons among means. J Hte Am Stat Assoc. 1961;56:52.View ArticleGoogle Scholar
  26. R Development Core Team. Vienna, Austria; 2008. https://www.r-project.org/. Accessed 14 Nov 2018.
  27. Bangham CRM, Araujo A, Yamano Y, Taylor GP. HTLV-1-associated myelopathy/tropical spastic paraparesis. Nat Rev Dis Primer. 2015;1:15012.View ArticleGoogle Scholar
  28. Afonso PV, Ozden S, Prevost M-C, Schmitt C, Seilhean D, Weksler B, et al. Human blood-brain barrier disruption by retroviral-infected lymphocytes: role of myosin light chain kinase in endothelial tight-junction disorganization. J Immunol Baltim Md 1950. 2007;179:2576–83.Google Scholar
  29. Wilson AG, di Giovine FS, Blakemore AI, Duff GW. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet. 1992;1:353.View ArticleGoogle Scholar
  30. Starling ALB, Martins-Filho OA, Lambertucci JR, Labanca L, de Souza Pereira SR, Teixeira-Carvalho A, et al. Proviral load and the balance of serum cytokines in HTLV-1-asymptomatic infection and in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Acta Trop. 2013;125:75–81.View ArticleGoogle Scholar
  31. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24:179–89.View ArticleGoogle Scholar
  32. Quaresma JAS, Yoshikawa GT, Koyama RVL, Dias GAS, Fujihara S, Fuzii HT. HTLV-1, Immune Response and Autoimmunity. Viruses. 2015;8:1-10.View ArticleGoogle Scholar
  33. Rocha-Júnior MC, Haddad R, Cilião Alves DC, de Deus Wagatsuma VM, Mendes-Junior CT, Deghaide NHS, et al. Interleukin-18 and interferon-gamma polymorphisms are implicated on proviral load and susceptibility to human T-lymphotropic virus type 1 infection. Tissue Antigens. 2012;80:143–50.View ArticleGoogle Scholar
  34. Zhao T, Satou Y, Sugata K, Miyazato P, Green PL, Imamura T, et al. HTLV-1 bZIP factor enhances TGF-β signaling through p300 coactivator. Blood. 2011;118:1865–76.View ArticleGoogle Scholar
  35. Nakamura H, Horai Y, Tokuyama A, Yoshimura S, Nakajima H, Ichinose K, et al. HTLV-I virological and histopathological analysis in two cases of anti-centromere-antibody-seropositive Sjögren’s syndrome. Mod Rheumatol. 2013;23:133–9.View ArticleGoogle Scholar
  36. Kim SJ, Kehrl JH, Burton J, Tendler CL, Jeang KT, Danielpour D, et al. Transactivation of the transforming growth factor beta 1 (TGF-beta 1) gene by human T lymphotropic virus type 1 tax: a potential mechanism for the increased production of TGF-beta 1 in adult T cell leukemia. J Exp Med. 1990;172:121–9.View ArticleGoogle Scholar
  37. Kim SJ, Winokur TS, Lee HD, Danielpour D, Kim KY, Geiser AG, et al. Overexpression of transforming growth factor-beta in transgenic mice carrying the human T-cell lymphotropic virus type I tax gene. Mol Cell Biol. 1991;11:5222–8.View ArticleGoogle Scholar
  38. Starling ALB, Coelho-Dos-Reis JGA, Peruhype-Magalhães V, Pascoal-Xavier MA, Gonçalves DU, Béla SR, et al. Immunological signature of the different clinical stages of the HTLV-1 infection: establishing serum biomarkers for HTLV-1-associated disease morbidity. Biomark Biochem Indic Expo Response Susceptibility Chem. 2015;20:502–12.Google Scholar
  39. Sabouri AH, Saito M, Lloyd AL, Vine AM, Witkover AW, Furukawa Y, et al. Polymorphism in the interleukin-10 promoter affects both provirus load and the risk of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Infect Dis. 2004;190:1279–85.View ArticleGoogle Scholar
  40. Catalan-Soares B, Carneiro-Proietti AB, Proietti FA, Interdisciplinary HTLV Research Group. Heterogeneous geographic distribution of human T-cell lymphotropic viruses I and II (HTLV-I/II): serological screening prevalence rates in blood donors from large urban areas in Brazil. Cad Saude Publica. 2005;21:926–31.View ArticleGoogle Scholar
  41. Vandamme AM, Salemi M, Desmyter J. The simian origins of the pathogenic human T-cell lymphotropic virus type I. Trends Microbiol. 1998;6:477–83.View ArticleGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement